BRIEF-Coherus Biosciences announces positive topline 24-week treatment Phase 3 results for CHS-1420 in patients with Psoriasis

* Coherus Biosciences announces positive topline 24-week treatment phase three results for CHS-1420 (HUMIRA biosimilar candidate) in patients with Psoriasis
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.